Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy

被引：0
|
作者：
Lee, A. [1 ]
Girling, B. [1 ]
Patel, G. [1 ]
Sawhney, P. [1 ]
Luong, M. [1 ]
Ohana, D. [1 ]
Forster, M. [1 ]
Lee, S. [1 ]
机构：
[1] Univ Coll London Hosp, Canc Div, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
immunotherapy; NSCLC; Toxicities;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA13.06
引用
下载
收藏
页码：S925 / S926
页数：2
相关论文
共 50 条
  • [1] Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy
    Maeda, Takuya
    Yoshino, Koji
    Nagai, Kojiro
    Oaku, Satoe
    Kato, Megumi
    Hiura, Azusa
    Hata, Hiroo
    EUROPEAN JOURNAL OF CANCER, 2019, 115 : 13 - 16
  • [2] Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors
    Serino, M.
    Freitas, C.
    Martins, M.
    Ferreira, P.
    Cardoso, C.
    Veiga, F.
    Santos, V.
    Araujo, D.
    Novais-Bastos, H.
    Magalhaes, A.
    Queiroga, H.
    Fernandes, G.
    Hespanhol, V.
    PULMONOLOGY, 2024, 30 (04): : 352 - 361
  • [3] CORRELATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS SPECTRUM AND PROGNOSIS IN PATIENTS WITH ADVANCED UROTHELIAL CANCER TREATED WITH PEMBROLIZUMAB
    Tamiya, Takashi
    Kijima, Toshiki
    Tanaka, Hajime
    Yoshida, Soichiro
    Ishioka, Junichiro
    Matsuoka, Yoh
    Numao, Noboru
    Sakai, Yasuyuki
    Saito, Kazutaka
    Matsubara, Nobuaki
    Yuasa, Takeshi
    Masuda, Hithoshi
    Yonese, Junji
    Kageyama, Yukio
    Fujii, Yasuhisa
    JOURNAL OF UROLOGY, 2020, 203 : E743 - E744
  • [4] Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab
    Mashni, Ola K.
    Baba, Dima W.
    Mahmoud, Aseel N.
    Qur'an, Tasnim O.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 577 - 581
  • [5] Prognostic impact of immune-related adverse events with nivolumab or pembrolizumab monotherapy in patients with advanced gastric cancer: A multicenter retrospective analysis
    Motoo, I.
    Ando, T.
    Ueda, A.
    Ogawa, K.
    Kajiura, S.
    Hirano, K.
    Okumura, T.
    Tsukada, K.
    Hara, T.
    Suzuki, N.
    Nakada, N.
    Takatori, S.
    Horikawa, N.
    Fujii, T.
    Yasuda, I.
    ANNALS OF ONCOLOGY, 2020, 31 : S148 - S148
  • [6] Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors
    Sanda, Gregory E.
    Shabto, Julie M.
    Goyal, Subir
    Liu, Yuan
    Martini, Dylan J.
    Nazha, Bassel
    Brown, Jacqueline T.
    Yantorni, Lauren B.
    Russler, Greta Anne
    Caulfield, Sarah
    Joshi, Shreyas S.
    Narayan, Vikram M.
    Kissick, Haydn
    Ogan, Kenneth
    Master, Viraj A.
    Carthon, Bradley C.
    Kucuk, Omer
    Bilen, Mehmet Asim
    ONCOLOGIST, 2023, : 1072 - 1078
  • [7] Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program
    Baldini, Editta
    Lunghi, Alice
    Cortesi, Enrico
    Turci, Daniele
    Signorelli, Diego
    Stati, Valeria
    Melotti, Barbara
    Ricciuti, Biagio
    Frassoldati, Antonio
    Romano, Giampiero
    Ceresoli, Giovanni Luca
    Illiano, Alfonso
    Verderame, Francesco
    Fasola, Gianpiero
    Ricevuto, Enrico
    Marchetti, Paolo
    Pinto, Carmine
    Carteni, Giacomo
    Scotti, Vieri
    Tibaldi, Carmelo
    Fioretto, Luisa
    Giannarelli, Diana
    LUNG CANCER, 2020, 140 : 59 - 64
  • [8] Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis
    Ando, Takayuki
    Ueda, Akira
    Ogawa, Kohei
    Motoo, Iori
    Kajiura, Shinya
    Nakajima, Takahiko
    Hirano, Katsuhisa
    Okumura, Tomoyuki
    Tsukada, Kenichiro
    Hara, Takuo
    Suzuki, Nobuhiro
    Nakada, Naokatsu
    Horikawa, Naoki
    Fujii, Tsutomu
    Yasuda, Ichiro
    IN VIVO, 2021, 35 (01): : 475 - 482
  • [9] Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
    Knox, A.
    Cloney, T.
    Janssen, H.
    Solomon, B.
    Alexander, M.
    John, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S1684 - S1684
  • [10] Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Cook, Sarah
    Samuel, Vanessa
    Meyers, Daniel E.
    Stukalin, Igor
    Litt, Ishjot
    Sangha, Randeep
    Morris, Don G.
    Heng, Daniel Y. C.
    Pabani, Aliyah
    Dean, Michelle
    Navani, Vishal
    JAMA NETWORK OPEN, 2024, 7 (01) : E2352302
12345